Iron sucrose + stannic protoporfin is under clinical development by Renibus Therapeutics and currently in Phase III for Acute Renal Failure (ARF) (Acute Kidney Injury). According to GlobalData, Phase III drugs for Acute Renal Failure (ARF) (Acute Kidney Injury) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Iron sucrose + stannic protoporfin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iron sucrose + stannic protoporfin overview
Iron sucrose in combination with Sn protoporphyrin is under development for the treatment of acute renal failure. The combination therapy is administered by intravenous route.
Renibus Therapeutics overview
Renibus Therapeutics(Renibus Therapeutic) is bio technology company. It focuses on developing therapies for acute and chronic kidney diseases. The company develops products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus Therapeutic’s pipeline includes RBT-1, RBT-3, RBT-9, RBT-2. It offers its business to the patients. Renibus Therapeutic is headquatered in Southlake, Texas, the US.
For a complete picture of Iron sucrose + stannic protoporfin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
